Thomas J Moutinho1, Deborah A Powers1, Gabriel F Hanson1, Shira Levy2, Rajiv Baveja3, Isabel Hefner2, Masouma Mohamed2, Alaa Abdelghani2, Robin L Baker3, Jason A Papin1, Sean R Moore4, Suchitra K Hourigan2,4,5,6. 1. Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, USA. 2. Inova Children's Hospital, Falls Church, Virginia, USA. 3. Fairfax Neonatal Associates, Falls Church, Virginia, USA. 4. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA. 5. Division of Pediatric Gastroenterology, Pediatric Specialists of Virginia, Fairfax, Virginia, USA. 6. Laboratory of Host Immunity and Microbiome, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
BACKGROUND: Parenteral nutrition-associated cholestasis (PNAC) in the neonatal intensive care unit (NICU) causes significant morbidity and associated healthcare costs. Laboratory detection of PNAC currently relies on elevated serum conjugated bilirubin levels in the aftermath of impaired bile flow. Here, we sought to identify fecal biomarkers, which when integrated with clinical data, would better predict risk for developing PNAC. METHODS: Using untargeted metabolomics in 200 serial stool samples from 60 infants, we applied statistical and machine learning approaches to identify clinical features and metabolic biomarkers with the greatest associative potential for risk of developing PNAC. Stools were collected prospectively from infants receiving PN with soybean oil-based lipid emulsion at a level IV NICU. RESULTS: Low birth weight, extreme prematurity, longer duration of PN, and greater number of antibiotic courses were all risk factors for PNAC (P < 0.05). We identified 78 stool biomarkers with early predictive potential (P < 0.05). From these 78 biomarkers, we further identified 12 sphingomyelin lipids with high association for the development of PNAC in precholestasis stool samples when combined with birth anthropometry. CONCLUSION: We demonstrate the potential for stool metabolomics to enhance early identification of PNAC risk. Earlier detection of high-risk infants would empower proactive mitigation with alterations to PN for at-risk infants and optimization of energy nutrition with PN for infants at lower risk.
BACKGROUND: Parenteral nutrition-associated cholestasis (PNAC) in the neonatal intensive care unit (NICU) causes significant morbidity and associated healthcare costs. Laboratory detection of PNAC currently relies on elevated serum conjugated bilirubin levels in the aftermath of impaired bile flow. Here, we sought to identify fecal biomarkers, which when integrated with clinical data, would better predict risk for developing PNAC. METHODS: Using untargeted metabolomics in 200 serial stool samples from 60 infants, we applied statistical and machine learning approaches to identify clinical features and metabolic biomarkers with the greatest associative potential for risk of developing PNAC. Stools were collected prospectively from infants receiving PN with soybean oil-based lipid emulsion at a level IV NICU. RESULTS: Low birth weight, extreme prematurity, longer duration of PN, and greater number of antibiotic courses were all risk factors for PNAC (P < 0.05). We identified 78 stool biomarkers with early predictive potential (P < 0.05). From these 78 biomarkers, we further identified 12 sphingomyelin lipids with high association for the development of PNAC in precholestasis stool samples when combined with birth anthropometry. CONCLUSION: We demonstrate the potential for stool metabolomics to enhance early identification of PNAC risk. Earlier detection of high-risk infants would empower proactive mitigation with alterations to PN for at-risk infants and optimization of energy nutrition with PN for infants at lower risk.
Authors: Lisa Ford; Adam D Kennedy; Kelli D Goodman; Kirk L Pappan; Anne M Evans; Luke A D Miller; Jacob E Wulff; Bobby R Wiggs; John J Lennon; Sarah Elsea; Douglas R Toal Journal: J Appl Lab Med Date: 2020-03-01
Authors: Erikka Loftfield; Emily Vogtmann; Joshua N Sampson; Steven C Moore; Heidi Nelson; Rob Knight; Nicholas Chia; Rashmi Sinha Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-19 Impact factor: 4.254
Authors: Benjamin J Callahan; Paul J McMurdie; Michael J Rosen; Andrew W Han; Amy Jo A Johnson; Susan P Holmes Journal: Nat Methods Date: 2016-05-23 Impact factor: 28.547
Authors: Suchitra K Hourigan; Thomas J Moutinho; Andrew Berenz; Jason Papin; Pallabi Guha; Lois Bangiolo; Sandra Oliphant; Marina Provenzano; Raj Baveja; Robin Baker; Thierry Vilboux; Shira Levy; Varsha Deopujari; James P Nataro; John E Niederhuber; Sean R Moore Journal: J Pediatr Gastroenterol Nutr Date: 2020-05 Impact factor: 2.839
Authors: Daniel E Almonacid; Laurens Kraal; Francisco J Ossandon; Yelena V Budovskaya; Juan Pablo Cardenas; Elisabeth M Bik; Audrey D Goddard; Jessica Richman; Zachary S Apte Journal: PLoS One Date: 2017-05-03 Impact factor: 3.752